My ePortfolio Register   

Treating ALL in young adults

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.01.17
Views: 171

Prof Nicolas Boissel - Hôpital Saint-Louis, Paris, France

Prof Boissel speaks with ecancer about results from the GRAALL-2005 study, which assessed the response of adolescent and young adult patients to HSCT and consolidation therapy.

He identifies Ph-like and ABL-like subgroup of patient genotypes which indicate a sensitivity to TKI therapy, and considers the case of a patient who, initially unresponsive to prednisone, responded well to blinatumomab and dasatinib therapy before stem cell transplant, and is now in remission. 


ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence